The Current Applications and Potential of Human Pluripotent Stem Cells

A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Stem Cells".

Deadline for manuscript submissions: 30 April 2024 | Viewed by 1812

Special Issue Editor

E-Mail Website
Guest Editor
Laboratory of Molecular Mechanisms of Hematologic Disorders and Therapeutic Implications, INSERM UMR 1163, Imagine Institute, Paris-Centre University, F-75015 Paris, France
Interests: hematology; oncology; stem cells

Special Issue Information

Dear Colleagues,

We are excited to announce a Special Issue in our journal Cells on the current applications and potential of human pluripotent stem cells.

We invite researchers to submit original articles, reviews, and commentaries that showcase their expertise and contribute to advancing the field. Topics of interest include (but are not limited to) medical applications of pluripotent stem cells in regenerative medicine, research on genetic diseases, toxicology and pharmacology applications, and advances in culturing and differentiating human pluripotent stem cells. We welcome submissions that demonstrate the potential of organoids and biomaterials for various applications.

We hope to receive high-quality submissions that inspire new directions in research and demonstrate the potential of pluripotent stem cells, organoids, and biomaterials for various applications. For any inquiries related to this Special Issue, please contact the Editorial Office.

Dr. Leila Maouche-Chretien
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • human pluripotent stem cells
  • disease modeling
  • tissue engineering
  • organoids
  • regenerative medicine
  • epigenetic

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:


16 pages, 13881 KiB  
Single-Cell Transcriptomics and In Vitro Lineage Tracing Reveals Differential Susceptibility of Human iPSC-Derived Midbrain Dopaminergic Neurons in a Cellular Model of Parkinson’s Disease
by Lucia F. Cardo, Jimena Monzón-Sandoval, Zongze Li, Caleb Webber and Meng Li
Cells 2023, 12(24), 2860; - 18 Dec 2023
Viewed by 1334
Advances in stem cell technologies open up new avenues for modelling development and diseases. The success of these pursuits, however, relies on the use of cells most relevant to those targeted by the disease of interest, for example, midbrain dopaminergic neurons for Parkinson’s [...] Read more.
Advances in stem cell technologies open up new avenues for modelling development and diseases. The success of these pursuits, however, relies on the use of cells most relevant to those targeted by the disease of interest, for example, midbrain dopaminergic neurons for Parkinson’s disease. In the present study, we report the generation of a human induced pluripotent stem cell (iPSC) line capable of purifying and tracing nascent midbrain dopaminergic progenitors and their differentiated progeny via the expression of a Blue Fluorescent Protein (BFP). This was achieved by CRISPR/Cas9-assisted knock-in of BFP and Cre into the safe harbour locus AAVS1 and an early midbrain dopaminergic lineage marker gene LMX1A, respectively. Immunocytochemical analysis and single-cell RNA sequencing of iPSC-derived neural cultures confirm developmental recapitulation of the human fetal midbrain and high-quality midbrain cells. By modelling Parkinson’s disease-related drug toxicity using 1-Methyl-4-phenylpyridinium (MPP+), we showed a preferential reduction of BFP+ cells, a finding demonstrated independently by cell death assays and single-cell transcriptomic analysis of MPP+ treated neural cultures. Together, these results highlight the importance of disease-relevant cell types in stem cell modelling. Full article
Show Figures

Figure 1

Planned Papers

The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.

Title: Challenging for the cell-based therapy with induced pluripotent stem cells for fibrosing interstitial lung diseases
Authors: Yusuke Nakamura; Seiji Niho; Yasuo Shimizu*
Affiliation: Department of Pulmonary Medicine and Clinical Immunology, Dokkyo Medical University School of Medicine, Mibu, Tochigi, Japan
Abstract: Fibrosing interstitial lung diseases (FILD), represented by idiopathic pulmonary fibrosis (IPF), are chronic progressive diseases with a poor prognosis. The management of these diseases is challenging and focuses mainly on the suppression of progression with anti-fibrotic drugs. Therefore, novel FILD treatments are needed to develop. In recent years, cell-based therapy using various stem cells has been investigated for FILD. The use of mesenchymal stem cells (MSCs) has been widely reported and the mechanisms include homing to the site of inflammation, immunomodulation, alveolar stability and protection against fibrosis. Pluripotent stem cells (PSCs), such as embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs), have also been reported to be effective in FILD, and iPSC-derived alveolar type 2 epithelial cells (ATII), which are involved in lung regeneration, also attenuate lung injury. However, therapeutic studies using PSCs for FILD have not been as well studied as with MSCs. This review focuses on the clinical application of iPSCs in FILD and describes 1) an overview of iPSCs and FILD, 2) FILD treatment with iPSCs, 3) FILD treatment with iPSC-derived cells, 4) problems with the use of iPSCs and 5) possibilities for FILD therapy with iPSC-cell-based therapy.

Back to TopTop